Matthew Fowler

Seagen and Genmab hope to receive accelerated approval from the FDA for tisotumab vedotin monotherapy as treatment for patients with cervical cancer in the recurrent or metastatic setting.

Data regarding patients with previous Hodgkin lymphoma and primary myelofibrosis diagnoses found associations with subsequent diagnosis of multiple myeloma.

OmniSeq is partnering with the University of Pittsburgh Medical Center to employ a gene expression assay investigating the potential for personalized immunotherapy combinations for patients with head and neck squamous cell carcinoma.

Data in The Lancet promoted a tolerable safety profile and future feasibility of UCART19 administration among patients with relapsed and refractory B cell ALL.

Research in the Journal of Clinical Oncology found an association between the combination of daratumumab, lenalidomide, and dexamethasone with improved patient-reported outcomes versus lenalidomide and dexamethasone alone.

These data are the first to demonstrate that JSP191 is safe and effective in in older adult patients undergoing nonmyeloablative allogeneic hematopoietic cell transplantation for MRD-positive acute myeloid leukemia or myelodysplastic syndrome.

Data published in Cancer found adjuvant radiotherapy after distal cholangiocarcinoma resection was associated with a survival benefit for patients, regardless of margin or nodal status.

Data examined the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism in patients with ovarian cancer.

Data published in Data in Brief described an analysis that examined palliative care use among different racial and ethnic groups with metastatic gynecologic cancers, including ovarian, cervical, and uterine cancer.

Racial and socioeconomic factors were associated with varying levels of survival for patients with limited-stage small cell lung cancer, with improved survival noted among African American and Asian patients compared with White patients.

CancerNetwork® spoke with the CEO of the Union for International Cancer Control to learn more about their efforts in oncology amidst the COVID-19 pandemic, and the work they are doing on World Cancer Day.

Data from this international study further developed the field of head and neck cancers, elaborating on contributions from key cancer-associated genes, proteins, and signaling pathways.

CancerNetwork®’s podcast features Justin Gregg, MD, lead author of a study investigating the Mediterranean diet and how it impacts men with localized prostate cancer.

An updated analysis presented at the 2020 World Conference on Lung Cancer Singapore expanded on data investigating pembrolizumab in the treatment of patients with PD-L1–positive NSCLC without sensitizing EGFR/ALK alterations.

Sohal spoke with CancerNetwork® regarding recent clinical data investigating 2 common pancreatic cancer treatment regimens: FOLFIRINOX and gemcitabine/nab-paclitaxel.

The randomized, open-label, phase 3 FeDeriCa trial tested the safety profile of pertuzumab and trastuzumab plus hyaluronidase-zzxf in 500 patients with HER2-positive early breast cancer.

A study found a number of factors associated with increased recurrence risk for patients with locally advanced pancreatic neuroendocrine tumors following surgical resection, including sex, lymph node metastases, and resection of other organs with tumor involvement.

Data published in JAMA Oncology found boosts in quality of life in addition to improvements in depression, anxiety, and posttraumatic stress symptoms for patients with acute myeloid leukemia receiving integrated palliative and oncology care.

Data published in Cancer the journal found that the response to neoadjuvant therapy in patients with retroperitoneal sarcoma following surgery was fair overall, with data suggesting the potential for disease progression as a predictive tool for patient survival.

Research published in JAMA Network Open found that total neoadjuvant therapy enhanced pathological complete response rates for patients with locally advanced rectal cancer.

Data published in The Lancet found a favorable tolerability profile for the subcutaneous formulation of bortezomib when compared with previous trials of the combination panobinostat plus dexamethasone and intravenous bortezomib in myeloma.

The latest episode of CancerNetwork®’s podcast examines a review article focusing on spinal metastases and stereotactic body radiation therapy.

Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life was steady and similar over the course of 18 weeks for patients receiving chemotherapy with or without pembrolizumab for esophageal cancer.

Investigators whose work was published in JAMA Network Open found that patients with low mammographic breast density were at higher risk of developing severe lymphedema.

An industry leader in psychosocial oncology detailed the importance of patient-reported outcomes to the field as a whole and emphasized a number of key details to remember when examining these end points.

A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.

Merus announced that their bispecific antibody was granted fast track designation by the FDA for treating NRG1 fusion–positive solid tumors.

The latest episode of CancerNetwork’s podcast features an exclusive conversation with an industry thought leader regarding smoking cessation and its impact on patients with cancer.

The latest episode of the “Oncology Peer Review On-The-Go” podcast discusses a review article on patient-reported outcomes of cancer-related pain.

Research presented at the 2020 SABCS found providers planned to use neoadjuvant endocrine therapy for as little as possible until surgery was available for patients with estrogen receptor positive breast cancer.